Mechanisms of platelet-stimulated colon cancer invasion: Role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway

Carcinogenesis

Volumn 35, Issue 2, 2014, Pages 324-332

  Radziwon Balicka, Aneta ^a   Santos Martinez, Maria J ^a,b   Corbalan, J Jose ^a   O'Sullivan, Shane ^a   Treumann, Achim ^c   Gilmer, John F ^a   Radomski, Marek W ^a   Medina, Carlos ^a  

^a School of Pharmacy and Pharmaceutical Sciences   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CLUSTERIN; CYCLOHEXIMIDE; DACTINOMYCIN; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE P38; PADGEM PROTEIN; SMALL INTERFERING RNA; THROMBOSPONDIN 1;

ARTICLE; CANCER CELL CULTURE; CELL INTERACTION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SCANNING ELECTRON MICROSCOPY; TANDEM MASS SPECTROMETRY; THROMBOCYTE; THROMBOCYTE AGGREGATION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOOD PLATELETS; BLOTTING, WESTERN; CACO-2 CELLS; CELL MOVEMENT; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; CLUSTERIN; COLONIC NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84893379832     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt332     Document Type: Article

References (48)

1. André,T. et al.; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med., 350, 2343-2351.
2. Steeg,P.S. (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer, 3, 55-63.
3. Trousseau,A. (1865) Clinique Medicale de L'Hotel-Dieu Paris. Vol. 3. New Sydenham Society, London, UK, pp. 94-96.
4. Abbasciano,V. et al. (1995) Platelet activation and fibrinolysis in large bowel cancer. Oncology, 52, 381-384.
5. Bambace,N.M. et al. (2011) The platelet contribution to cancer progression. J. Thromb. Haemost., 9, 237-249.
6. Monreal,M. et al. (1998) Platelet count and survival in patients with colorectal cancer-a preliminary study. Thromb. Haemost., 79, 916-918.
7. Jurasz,P. et al. (2004) Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol., 143, 819-826.
8. Medina,C. et al. (2006) Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J. Pharmacol. Exp. Ther., 317, 739-745.
9. Gupta,G.P. et al. (2004) Platelets and metastasis revisited: a novel fatty link. J. Clin. Invest., 114, 1691-1693.
10. Alonso-Escolano,D. et al. (2006) Protein kinase C delta mediates platelet-induced breast cancer cell invasion. J. Pharmacol. Exp. Ther., 318, 373-380.
11. Yurchenco,P.D. et al. (1990) Molecular architecture of basement membranes. FASEB J., 4, 1577-1590.
12. Pupa,S.M. et al. (2002) New insights into the role of extracellular matrix during tumor onset and progression. J. Cell. Physiol., 192, 259-267.
13. Alonso-Escolano,D. et al. (2004) Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br. J. Pharmacol., 141, 241-252.
14. Gialeli,C. et al. (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J., 278, 16-27.
15. Gimeno-García,A.Z. et al. (2006) Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. Eur. J. Cancer, 42, 3246-3252.
16. Lubbe,W.J. et al. (2006) Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin. Cancer Res., 12, 1876-1882.
17. Zucker,S. et al. (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene, 19, 6642-6650.
18. Dormán,G. et al. (2010) Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs, 70, 949-964.
19. Van den Steen,P.E. et al. (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol., 37, 375-536.
20. Kim,E.K. et al. (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta, 1802, 396-405.
21. Yong,H.Y. et al. (2009) The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin. Investig. Drugs, 18, 1893-1905.
22. Radomski,M. et al. (1983) An improved method for washing of human platelets with prostacyclin. Thromb. Res., 30, 383-389.
23. Wang,S. et al. (2010) Glucose downregulation of PKG-I protein mediates increased thrombospondin 1-dependent TGF-{beta} activity in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol., 298, C1188-C1197.
24. Redondo,M. et al. (2007) Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Breast Cancer Res., 9, R86.
25. Medina,C. et al. (2006) Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J. Leukoc. Biol., 79, 954-962.
26. Kessner,D. et al. (2008) ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics, 24, 2534-2536.
27. Craig,R. et al. (2004) TANDEM: matching proteins with tandem mass spectra. Bioinformatics, 20, 1466-1467.
28. Radziwon-Balicka,A. et al. (2012) Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br. J. Pharmacol., 167, 787-804.
29. Woessner,J.F. Jr. (1999) Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann. N. Y. Acad. Sci., 878, 388-403.
30. Jurasz,P. et al. (2001) Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res., 61, 376-382.
31. Liotta,L.A. et al. (1990) Metalloproteinases and cancer invasion. Semin. Cancer Biol., 1, 99-106.
32. Gomes,L.R. et al. (2012) TGF-ß1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer, 12, 26.
33. Santarpia,L. et al. (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets, 16, 103-119.
34. Takahashi,K. et al. (2009) Epigenetic regulation of TLR4 gene expression in intestinal epithelial cells for the maintenance of intestinal homeostasis. J. Immunol., 183, 6522-6529.
35. Chen,Y.J. et al. (2010) Involvement of p38 MAPK- and JNK-modulated expression of Bcl-2 and Bax in Naja nigricollis CMS-9-induced apoptosis of human leukemia K562 cells. Toxicon, 55, 1306-1316.
36. Lin,C.C. et al. (2009) IL-1 beta promotes A549 cell migration via MAPKs/AP-1- and NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell. Signal., 21, 1652-1662.
37. Yen,J.H. et al. (2011) Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation. J. Biol. Chem., 286, 38913-38923.
38. Li,J. et al. (2012) Stable knockdown of clusterin by vector based RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis. J. Int. Med. Res., 40, 545-555.
39. Simon,C. et al. (1998) Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res., 58, 1135-1139.
40. Hsu,H.H. et al. (2012) p38a MAPK mediates 17ß-estradiol inhibition of MMP-2 and -9 expression and cell migration in human lovo colon cancer cells. J. Cell. Physiol., 227, 3648-3660.
41. Sargiannidou,I. et al. (2004) Mechanisms of thrombospondin-1-mediated metastasis and angiogenesis. Semin. Thromb. Hemost., 30, 127-136.
42. Foss,B. et al. (2001) Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur. J. Haematol., 67, 267-278.
43. Redondo,M. et al. (2010) Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas. Histopathology, 56, 932-936.
44. Sundaram,P. et al. (2011) p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res., 71, 7490-7501.
45. Tsuchida,T. et al. (1999) Expression of the thrombospondin 1 receptor CD36 is correlated with decreased stromal vascularisation in colon cancer. Int. J. Oncol., 14, 47-51.
46. Broom,O.J. et al. (2009) CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration. PLoS One, 4, e6371.
47. Qian,X. et al. (2001) Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol. Oncol. Res., 7, 251-259.
48. Shim,Y.J. et al. (2011) Clusterin induces matrix metalloproteinase-9 expression via ERK1/2 and PI3K/Akt/NF-κB pathways in monocytes/macrophages. J. Leukoc. Biol., 90, 761-769.